Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence

Cancer Biomarkers

Volumn 11, Issue 2-3, 2012, Pages 59-73

  Chatterjee, Madhumita ^a,b   Dyson, Greg ^a   Levin, Nancy K ^a,b   Shah, Jay P ^c   Morris, Robert ^b   Munkarah, Adnan ^b,d   Tainsky, Michael A ^a,b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAISER PERMANENTE   (United States)

^d HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

humoral immune response; Ovarian cancer; protein arrays; recurrence; tumor autoantibodies

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CA 125 ANTIGEN; MEC1 4B7; MEC1 4H4; MEC1 5H6; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVARY CARCINOMA; PILOT STUDY; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN MICROARRAY; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS;

ADULT; AGED; ANTIBODIES, NEOPLASM; AUTOANTIBODIES; CA-125 ANTIGEN; FEMALE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867560355     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2012-0265     Document Type: Article

References (27)

1. J.C. Schink, Current initial therapy of stage III and IV ovarian cancer: challenges for managed care, Semin Oncol 26 (1999), 2-7. (Pubitemid 29093792)
2. D.G. Mutch, Surgical management of ovarian cancer, Semin Oncol 29 (2002), 3-8. (Pubitemid 34163835)
3. P.E. Schwartz, Current diagnosis and treatment modalities for ovarian cancer, Cancer Treat Res 107 (2002), 99-118.
4. T.C. Chua, W. Liauw, G. Robertson and D.L. Morris, Secondline treatment of first relapse recurrent ovarian cancer, Aust N Z J Obstet Gynaecol 50 (2010), 465-471.
5. W.J.Mann, B. Patsner, H. Cohen and M. Loesch, Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma, J Natl Cancer Inst 80 (1988), 208-209.
6. T.C. Krivak, C. Tian, G.S. Rose, D.K. Armstrong and G.L. Maxwell, A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172, Gynecol Oncol 115 (2009), 81-85.
7. J.L. Wilder, E. Pavlik, J.M. Straughn, T. Kirby, R.V. Higgins, P.D. DePriest, F.R. Ueland, R.J. Kryscio, R.J. Whitley and J. Nagell, Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation, Gynecol Oncol 89 (2003), 233-235. (Pubitemid 36457870)
8. Y. Li, A. Karjalainen, H. Koskinen, K. Hemminki, H. Vainio, M. Shnaidman, Z. Ying, E. Pukkala and P.W. Brandt-Rauf, p53 autoantibodies predict subsequent development of cancer, Int J Cancer 114 (2005), 157-160. (Pubitemid 40194322)
9. M. Chatterjee, S. Mohapatra, A. Ionan, G. Bawa, R. Ali-Fehmi, X. Wang, J. Nowak, B. Ye, F.A. Nahhas, K. Lu, S.S. Witkin, D. Fishman, A. Munkarah, R. Morris, N.K. Levin, N.N. Shirley, G. Tromp, J. Abrams, S.Draghici andM.A. Tainsky, Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays, Cancer Res 66 (2006), 1181-1190. (Pubitemid 43165989)
10. S. Draghici, M. Chatterjee and M.A. Tainsky, Epitomics: serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens, Expert Rev Mol Diagn 5 (2005), 735-743. (Pubitemid 41337468)
11. O.M. Howard, H.F. Dong, D. Yang, N. Raben, K. Nagaraju, A. Rosen, L. Casciola-Rosen, M. Hartlein, M. Kron, D. Yang, K. Yiadom, S. Dwivedi, P.H. Plotz and J.J. Oppenheim, Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells, J Exp Med 196 (2002), 781-791.
12. C.Iavazzo, G. Vorgias, M. Papadakis, P. Manikis, I. Mavromatis and T. Akrivos, Polymyositis in a patient with recurring ovarian cancer and history of unrelated breast cancer, Arch Gynecol Obstet 276 (2007), 81-84. (Pubitemid 46889545)
13. G.J. Rustin, A.E. Nelstrop, M.K. Tuxen and H.E. Lambert, Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study, Ann Oncol 7 (1996), 361-364. (Pubitemid 26246787)
14. J.J. Wasmuth and L.R. Carlock, Chromosomal localization of human gene for histidyl-tRNA synthetase: clustering of genes encoding aminoacyl-tRNA synthetases on human chromosome 5, Somat Cell Mol Genet 12 (1986), 513-517. (Pubitemid 16030771)
15. A.Ghosh, T.M.Malak andA.J. Pool, Polymyositis and ovarian carcinoma: a case report, Arch Gynecol Obstet 275 (2007), 195-197. (Pubitemid 46221276)
16. B. Sigurgeirsson, B. Lindelof, O. Edhag and E. Allander, Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study, N Engl J Med 326 (1992), 363-367.
17. M.H.V. Regenmortel, Molecular dissection of protein antigens and the prediction of epitopes. In: Van Regenmortel MHV, Muller S (eds) Synthetic Peptides as Antigens. Amsterdam, Elsevier, (1999), pp. 1-78.
18. R.H. Meloen, W.C. Puijk and J.W. Slootstra, Mimotopes: realization of an unlikely concept, J Mol Recognit 13 (2000), 352-359.
19. E. Anastasi, G.G.Marchei, V. Viggiani, G. Gennarini, L. Frati and M.G. Reale, HE4: a new potential early biomarker for the recurrence of ovarian cancer, Tumour Biol 31 (2010), 113-119.
20. J.O.Schorge, R.D. Drake, H. Lee, S.J. Skates, R. Rajanbabu, D.S.Miller, J.H. Kim, D.W. Cramer, R.S. Berkowitz and S.C. Mok, Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer, Clin Cancer Res 10 (2004), 3474-3478. (Pubitemid 38685455)
21. R.A. Tassi, S. Calza, A. Ravaggi, E. Bignotti, F.E. Odicino, G. Tognon, C. Donzelli, M. Falchetti, E. Rossi, P. Todeschini, C. Romani, E. Bandiera, L. Zanotti, S. Pecorelli and A.D. Santin, Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence, BMCCancer 9 (2009), 253.
22. L.J. Havrilesky, C.M. Whitehead, J.M. Rubatt, R.L. Cheek, J. Groelke, Q. He, D.P. Malinowski, T.J. Fischer and A. Berchuck, Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence, Gynecol Oncol 110 (2008), 374-382.
23. F.D. Vogl, E. Stickeler, M. Weyermann, T. Kohler, H.J. Grill, G. Negri, R. Kreienberg and I.B. Runnebaum, p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells, Oncology 57 (1999), 324-329.
24. G.J. Rustin, M.E. van der Burg, C.L. Griffin, D. Guthrie, A. Lamont, G.C. Jayson, G. Kristensen, C. Mediola, C. Coens, W. Qian, M.K. Parmar and A.M. Swart, Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial, Lancet 376 (2010), 1155-1163.
25. R.T.Morris and B.J. Monk, Ovarian cancer: relevant therapy, not timing, is paramount, Lancet 376 (2010), 1120-1122.
26. S. Sivori, S. Parolini, E. Marcenaro, R. Castriconi, D. Pende, R. Millo and A. Moretta, Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines, J Neuroimmunol 107 (2000), 220-225. (Pubitemid 30347431)
27. J. Yu, Q. Tao, K.F. Cheung, H. Jin, F.F. Poon, X. Wang, H. Li, Y.Y. Cheng, C. Rocken, M.P. Ebert, A.T. Chan and J.J. Sung, Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors, Hepatology 48 (2008), 508-518.